Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (2805/1)
International Centers for Precision Oncology
Universität Hamburg
- License Information
-
More Information
Article History
Received: 29 January 2025
Accepted: 24 April 2025
First Online: 8 May 2025
Declarations
:
: RPB is president of ICPO Academy and chairman of the scientific board of ICPO. ICPO Foundation had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
: Not applicable, because all data was taken from published sources and aggregated cost data was used. No individual patient data was collected for the purpose of this study.
: Not applicable. All data was taken from published sources and aggregated cost data was used, so no ethics approval was obtained.
: CB and TS have no relevant financial or non-financial interests to disclose. RPB reports: (i) Consultant—Sponsor: Curanosticum Wiesbaden-Frankfurt. Scientific Advisory Board (SAB), Consulting. (ii) Sponsor—ITM, 3B Pharma (3BP), Telix, Sinotau, Jiangsu Huayi Technology (JHT), Full LifeTechnologies, Portland Holding, z Alpha, Novartis.
